Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/SUNPHARMA stock hub

NSE/SUNPHARMA has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/SUNPHARMAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

4.4T

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/SUNPHARMA

In the news

Latest news · NSE/SUNPHARMA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E36

P25 24.9P50 32.4P75 45.7

Trailing P/E40.7

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC18.3

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/SUNPHARMA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

204

Groups with data

Currency

INR

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	43,000
Employees Change	2,000%
Employees Change Percent	4.88
Enterprise value	INR 4.2T
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE044A01036
Last refreshed	2026-05-10
Market cap	INR 4.4T
Price	INR 1,845
Price currency	INR
Rev Per Employee	13,211,416.28x
Sector	Healthcare
Sic	2834
Symbol	nse/SUNPHARMA
Website	https://sunpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.46%
EV Earnings	38.57x
EV/EBIT	30.94x
EV/EBITDA	26.12x
EV/Sales	7.41x
Forward P/E	36.01x
P/B ratio	5.68x
P/E ratio	40.66x
P/S ratio	7.8x
PE Ratio10 Y	42.67x
PE Ratio3 Y	36.05x
PE Ratio5 Y	40.14x
PEG ratio	2.61x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	24.04%
EBITDA Margin	28.21%
Gross margin	78.54%
Gross Profit	INR 446.2B
Gross Profit Growth	10.63%
Gross Profit Growth Q	15%
Gross Profit Growth3 Y	13%
Gross Profit Growth5 Y	13.24%
Net Income	INR 109.2B
Net Income Growth	-4.54%
Net Income Growth Q	16.03%
Net Income Growth Quarters	2%
Net Income Growth Years	4%
Net Income Growth3 Y	37.36%
Net Income Growth5 Y	35.28%
Pretax Margin	26.01%
Profit Margin	19.21%
Profit Per Employee	INR 2.5M
Profitable Years	22
Roa5y	7.57
Roe5y	11.54
ROIC	18.26
Roic5y	16.62

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	9.58%
Cagr15y	16.04%
Cagr1y	4.6%
Cagr20y	17.48%
Cagr3y	25.04%
Cagr5y	23.33%
Div CAGR10	18.59%
Div CAGR3	16.26%
Div CAGR5	20.48%
EPS Growth	-4.73
EPS Growth Q	15.7
EPS Growth Quarters	2
EPS Growth Years	4
EPS Growth3 Y	37.43
EPS Growth5 Y	35.25
Revenue Growth	10.09x
Revenue Growth Q	13.49x
Revenue Growth Quarters	22x
Revenue Growth Years	7x
Revenue Growth3 Y	10.24x
Revenue Growth5 Y	11.37x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 278.8B
Debt	INR 52.2B
Debt EBITDA	INR 0.32
Debt Equity	INR 0.07
Equity	INR 781.3B
Interest Coverage	45.2
Net Cash	INR 226.7B
Net Cash By Market Cap	INR 5.11
Net Cash Growth	29.15%
Net Debt EBITDA	INR -1.41
Net Debt Equity	INR -0.29
Tangible Book Value	INR 548.6B
Tangible Book Value Per Share	INR 229
WACC	4.78

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.24%
Dividend Growth	6.45%
Dividend Growth Years	7%
Dividend per share	INR 16
Dividend Years	26
Dividend Yield	0.87%
Ex Div Date	2026-02-05
Last Dividend	INR 11
Payout Frequency	Semi-Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	149.63%
1Y total return	4.59%
200-day SMA	1,702.7
3Y total return	95.55%
50-day SMA	1,751.1
50-day SMA vs 200-day SMA	50over200
5Y total return	185.29%
All Time High	1,960.4
All Time High Change	-5.88%
All Time High Date	2024-09-30
All Time Low	1.65
All Time Low Change	111,718.18%
All Time Low Date	1996-11-22
ATR	45.09
Beta	0.1
Beta1y	-0.11
Beta2y	0.16
Ch YTD	7.29
High	1,857.5
High52	1,857.8
High52 Date	2026-05-06
High52ch	-0.69%
Low	1,819.2
Low52	1,548
Low52 Date	2025-09-26
Low52ch	19.19%
Ma50ch	5.36%
Price vs 200-day SMA	8.36%
RSI	65.24
RSI Monthly	59.61
RSI Weekly	59.38
Sharpe ratio	-0.01x
Sortino ratio	0.27
Total Return	0.63%
Tr YTD	7.98
Tr15y	831.78%
Tr1m	7.39%
Tr1w	1.18%
Tr3m	8.84%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 136.6B
Operating Income Growth	11.21
Operating Income Growth Q	14.05
Operating Income Growth3 Y	15.97
Operating Income Growth5 Y	18.43
Operating margin	24.04

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,064,916,349%
Shares Insiders	12.01%
Shares Institutions	29.79%
Shares Out	2,399,334,970
Shares Qo Q	0.33%
Shares Yo Y	0.24%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	6,034,029.15x
Bv Per Share	324.5
Ch10y	129.4
Ch15y	736.6
Ch1m	7.39
Ch1w	1.18
Ch1y	3.58
Ch20y	1,903.9
Ch3m	8.84
Ch3y	90.12
Ch5y	171.5
Ch6m	9.08
Change	0.58%
Change From Open	1.26
Close	1,834.4
Days Gap	-0.68
Depreciation Amortization	23,674,175,000
Dollar Volume	5,235,562,035
Earnings Date	2026-05-22
EBIT	INR 136.6B
EBITDA	INR 160.2B
EPS	INR 45.45
F Score	2
Fiscal Year End	March
Founded	1,983
Graham Number	576.04323
Graham Upside	-68.78
Income Tax	INR 38.2B
Is Primary Listing	1
Last Earnings Date	2026-01-31
Last Report Date	2025-12-31
Last Split Date	2013-07-29
Last Split Type	Forward
Lynch Fair Value	INR 1,136
Lynch Upside	-38.41
Ma150	1,725.3
Ma150ch	6.94%
Ma20	1,731.8
Ma20ch	6.54%
Next Earnings Date	2026-05-22
Open	1,822
Payment Date	2026-02-16
Position In Range	67.36
Price Date	2026-05-08
Price EBITDA	INR 27.67
Ptbv Ratio	8.08
Relative Volume	0.47x
Revenue	568,090,900,000x
Tax By Revenue	6.73x
Tax Rate	25.86%
Tr20y	2,406.43%
Tr6m	9.79%
Volume	2,837,703

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/SUNPHARMA dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.9%

$16.0 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+20.5%

7 consecutive years of growth

Total shareholder yield

+0.6%

Next ex-dividend date: 2026-02-05

Performance

NSE/SUNPHARMA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/SUNPHARMA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+29.8%

Share of float held by funds and institutions

Insider ownership

+12.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.2%

Negative means the company is buying back shares.

Technical

NSE/SUNPHARMA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

65.2

Neutral momentum band

Price vs 200-day MA

+8.4%

50/200-day relationship not available

Beta (5Y)

0.10

Less volatile than the market

Sharpe ratio

-0.01

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/SUNPHARMA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/SUNPHARMA stock rating?

nse/SUNPHARMA is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/SUNPHARMA analysis?

The full report lives at /stocks/nse/SUNPHARMA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/SUNPHARMA?

The latest report frames nse/SUNPHARMA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/SUNPHARMA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.